| 4.74 0.06 (1.28%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.54 | 1-year : | 6.48 |
| Resists | First : | 4.75 | Second : | 5.54 |
| Pivot price | 3.86 |
|||
| Supports | First : | 3.98 | Second : | 3.5 |
| MAs | MA(5) : | 4.28 |
MA(20) : | 3.85 |
| MA(100) : | 3.72 |
MA(250) : | 4.27  |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 78.7 |
D(3) : | 58.8 |
| RSI | RSI(14): 70.4 |
|||
| 52-week | High : | 6.18 | Low : | 3.35 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MOLN ] has closed above the upper band by 9.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 192.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.75 - 4.76 | 4.76 - 4.78 |
| Low: | 3.93 - 3.95 | 3.95 - 3.97 |
| Close: | 4.7 - 4.74 | 4.74 - 4.77 |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Mon, 03 Nov 2025
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025 - The Manila Times
Mon, 03 Nov 2025
Molecular Partners (NASDAQ: MOLN) to present MP0533 AML poster at ASH 2025, Phase 1/2a - Stock Titan
Mon, 03 Nov 2025
Molecular Partners (NASDAQ: MOLN) shows selective CD3 Switch-DARPin targeting MSLN/EpCAM - Stock Titan
Thu, 30 Oct 2025
Molecular Partners Advances Clinical Pipeline with New IND Filing and Financial Update - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 1.748e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 30 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.934e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 843.4 % |
| Return on Equity (ttm) | -25.6 % |
| Qtrly Rev. Growth | 681000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -114.94 |
| EBITDA (p.s.) | -9.82791e+007 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 0.71 |
| Dividend | 0 |
| Forward Dividend | 29050 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|